Improved systemic pharmacokinetics, biodistribution, and antitumor activity of CpG oligodeoxynucleotides complexed to endogenous antibodies in vivo

Journal of Controlled Release

Volumn 120, Issue 1-2, 2007, Pages 95-103

  Palma, Enzo ^a   Cho, Moo J ^a  

^a UNIVERSITY OF NORTH CAROLINA   (United States)

Author keywords

CpG oligodeoxynucleotides; Intravenous pharmacokinetics; Monomeric immune complexes; Tissue distribution; Tumor growth inhibition

Indexed keywords

ANTIBODIES; DRUG PRODUCTS; PHARMACOKINETICS; TUMORS;

BIODISTRIBUTION; CPG OLIGODEOXYNUCLEOTIDES; TISSUE DISTRIBUTION; TUMOR GROWTH INHIBITION;

OLIGOMERS;

CPG OLIGODEOXYNUCLEOTIDE; DINITROPHENYLHAPTEN; IMMUNOGLOBULIN G; TRITIUM;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER INHIBITION; CONTROLLED STUDY; DRUG ACTIVITY; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG HALF LIFE; HISTOPATHOLOGY; IN VIVO STUDY; LIQUID SCINTILLATION COUNTING; MOUSE; NONHUMAN; PRIORITY JOURNAL;

ANIMALS; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CHEMISTRY, PHARMACEUTICAL; COLORECTAL NEOPLASMS; DINITROBENZENES; DRUG CARRIERS; HALF-LIFE; HAPTENS; IMMUNIZATION; IMMUNOGLOBULIN G; INJECTIONS, INTRAVENOUS; METABOLIC CLEARANCE RATE; MICE; MICE, INBRED BALB C; NECROSIS; OLIGODEOXYRIBONUCLEOTIDES; TIME FACTORS; TISSUE DISTRIBUTION;

EID: 34249886784     PISSN: 01683659     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jconrel.2007.03.016     Document Type: Article

References (41)

1. Krieg A.M. CpG motifs in bacterial DNA and their immune effects. Annu. Rev. Immunol. 20 (2002) 709-760
2. Krieg A.M. Antitumor applications of stimulating toll-like receptor 9 with CpG oligodeoxynucleotides. Curr. Oncol. Rep. 6 (2004) 88-95
3. Stacey K.J., Young G.R., Clark F., Sester D.P., Roberts T.L., Naik S., et al. The molecular basis for the lack of immunostimulatory activity of vertebrate DNA. J. Immunol. 170 (2003) 3614-3620
4. Vollmer J., Weeratna R., Payette P., Jurk M., Schetter C., Laucht M., et al. Characterization of three CpG oligodeoxynucleotide classes with distinct immunostimulatory activities. Eur. J. Immunol. 34 (2004) 251-262
5. Heckelsmiller K., Rall K., Beck S., Schlamp A., Seiderer J., Jahrsdorfer B., et al. Peritumoral CpG DNA elicits a coordinated response of CD8 T cells and innate effectors to cure established tumors in a murine colon carcinoma model. J. Immunol. 169 (2002) 3892-3899
6. Kawarada Y., Ganss R., Garbi N., Sacher T., Arnold B., and Hammerling G.J. NK- and CD8+ T cell-mediated eradication of established tumors by peritumoral injection of CpG-containing oligodeoxynucleotides. J. Immunol. 167 (2001) 5247-5253
7. Whitmore M.M., Li S., Falo Jr. L., and Huang L. Systemic administration of LPD prepared with CpG oligonucleotides inhibits the growth of established pulmonary metastases by stimulating innate and acquired antitumor immune responses. Cancer Immunol. Immunother. 50 (2001) 503-514
8. Crooke S.T., Graham M.J., Zuckerman J.E., Brooks D., Conklin B.S., Cummins L.L., et al. Pharmacokinetic properties of several novel oligonucleotide analogs in mice. J. Pharmacol. Exp. Ther. 277 (1996) 923-937
9. Mutwiri G.K., Nichani A.K., Babiuk S., and Babiuk L.A. Strategies for enhancing the immunostimulatory effects of CpG oligodeoxynucleotides. J. Control. Release 97 (2005) 1-17
10. Matsumura Y., and Maeda H. A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent Smancs. Cancer Res. 46 (1986) 6387-6392
11. Noguchi Y., Wu J., Duncan R., Strohalm J., Ulbrich K., Akaike T., et al. Early phase tumor accumulation of macromolecules: a great difference in clearance rate between tumor and normal tissue. Jpn. J. Cancer Res. 89 (1998) 307-314
12. Maeda H., Wu J., Sawa T., Matsumura Y., and Hori K. Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review. J Control. Release 65 (2000) 271-284
13. Duncan R. Polymer conjugates for tumour targeting and intracytoplasmic delivery. The EPR effect as a common gateway?. Pharm. Sci. Technol. Today 2 (1999) 441-449
14. McDonald D.M., and Baluk P. Significance of blood vessel leakiness in cancer. Cancer Res. 62 (2002) 5381-5385
15. Padera T.P., Kadambi A., di Tomaso E., Carreira C.M., Brown E.B., Boucher Y., et al. Lymphatic metastasis in the absence of functional intratumor lymphatics. Science 296 (2002) 1883-1886
16. Nakahara T., Norberg S.M., Shalinsky D.R., Hu-Lowe D.D., and McDonald D.M. Effect of inhibition of vascular endothelial growth factor signaling on distribution of extravasated antibodies in tumors. Cancer Res. 66 (2006) 1434-1445
17. Takakura Y., Fujita T., Hashida M., and Sezaki H. Disposition characteristics of macromolecules in tumor-bearing mice. Pharm. Res. 7 (1990) 339-346
18. Skogh T., Stendahl O., Sundqvist T., and Edebo L. Physiochemical properties and blood clearance of human serum albumin conjugated to different extents with dinitrophenyl groups. Int. Arch. Allergy Appl. Immun. 70 (1983) 238-241
19. Rehlaender B.N., and Cho M.J. Anti-drug antibodies as drug carriers. I. For small molecules. Pharm. Res. 18 (2001) 745-752
20. Rehlaender B.N., and Cho M.J. Antibodies as drug carriers. II. For proteins. Pharm. Res. 18 (2001) 753-760
21. O'Hear C.E., and Foote J. Antibody buffering of a ligand in vivo. Proc. Natl. Acad. Sci. U. S. A. 102 (2005) 40-44
22. Palma E., Klapper D.G., and Cho M.J. Antibodies as drug carriers III: design of oligonucleotides with enhanced binding affinity for immunoglobulin G. Pharm. Res. 22 (2005) 122-127
23. Kandimalla E.R., Bhagat L., Yu D., Cong Y., Tang J., and Agrawal S. Conjugation of ligands at the 5′-end of CpG-DNA affects immunostimulatory activity. Bioconjug. Chem. 13 (2002) 966-974
24. Graham M.J., Freier S.M., Crooke R.M., Ecker D.J., Maslova R.N., and Lesnik E.A. Tritium labeling of antisense oligonucleotides by exchange with tritiated water. Nucleic Acids Res. 21 (1993) 3737-3743
25. 3H]muramyl tripeptide phosphatidylethanolamine in mice. J. Immunol. 135 (1985) 1372-1377
26. Heikenwalder M., Polymenidou M., Junt T., Sigurdson C., Wagner H., Akira S., et al. Lymphoid follicle destruction and immunosuppression after repeated CpG oligodeoxynucleotide administration. Nat. Med. 10 (2004) 187-192
27. Sparwasser T., Hultner L., Koch E.S., Luz A., Lipford G.B., and Wagner H. Immunostimulatory CpG-oligodeoxynucleotides cause extramedullary murine hemopoiesis. J. Immunol. 162 (1999) 2368-2374
28. Junghans R.P., and Anderson C.L. The protection receptor for IgG catabolism is the b2-microglobulin-containing neonatal intestinal transport receptor. Proc. Natl. Acad. Sci. U. S. A. 93 (1996) 5512-5516
29. Lencer W.I., and Blumberg R.S. A passionate kiss, then run: exocytosis and recycling of IgG by FcRn. Trends Cell Biol. 15 (2005) 5-9
30. Caliceti P., and Veronese F.M. Pharmacokinetic and biodistribution properties of poly(ethylene glycol)-protein conjugates. Adv. Drug. Deliv. Rev. 55 (2003) 1261-1277
31. Schumaker V.N., Green G., and Wilder R.L. A theory of bivalent antibody-bivalent hapten interactions. Immunochemistry 10 (1973) 521-528
32. Wilder R.L., Green G., and Schumaker V.N. Bivalent hapten-antibody interactions - I. A comparison of water soluble and water insoluble bivalent hapten. Immunochemistry 12 (1975) 39-47
33. Braeckmann R. In: Reid R.E. (Ed). Peptide and Protein Drug Analysis (2000), Marcel Dekker, Inc, New York 633-669
34. Racanelli V., and Rehermann B. The liver as an immunological organ. Hepatology 43 (2006) S54-S62
35. Haymann J.P., Levraud J.P., Bouet S., Kappes V., Hagege J., Nguyen G., et al. Characterization and localization of the neonatal Fc receptor in adult human kidney. J. Am. Soc. Nephrol. 11 (2000) 632-639
36. Kobayashi N., Suzuki Y., Tsuge T., Okumura K., Ra C., and Tomino Y. FcRn-mediated transcytosis of immunoglobulin G in human renal proximal tubular epithelial cells. Am. J. Physiol. Renal Physiol. 282 (2002) F358-F365
37. Lewis C.E., and Pollard J.W. Distinct role of macrophages in different tumor microenvironments. Cancer Res. 66 (2006) 605-612
38. Krall G., and Mebius R. New insights into the cell biology of the marginal zone of the spleen. Int. Rev. Cyt. 250 (2006) 175-215
39. Seymour L.W., Miyamoto Y., Maeda H., Brereton M., Strohalm J., Ulbrich K., et al. Influence of molecular weight on passive tumour accumulation of a soluble macromolecular drug carrier. Eur. J. Cancer 31A (1995) 766-770
40. Ishida O., Maruyama K., Tanahashi H., Iwatsuru M., Sasaki K., Eriguchi M., et al. Liposomes bearing polyethyleneglycol-coupled transferrin with intracellular targeting property to the solid tumors in vivo. Pharm. Res. 18 (2001) 1042-1048
41. Mandler R., Kobayashi H., Hinson E.R., Brechbiel M.W., and Waldmann T.A. Herceptin-geldanamycin immunoconjugates: pharmacokinetics, biodistribution, and enhanced antitumor activity. Cancer Res. 64 (2004) 1460-1467